The present invention relates to compounds that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, such as cells undergoing apoptosis or activated platelets. The invention further provides methods for utilizing said compounds in medical practice, for diagnostic and therapeutic purposes.
CROSS REFERENCE DATA
This application claims the priority of U.S. Provisional Application No. 60/536,493, filed Jan. 15, 2004 and U.S. Provisional Application No. 60/537,289, filed Jan. 20, 2004, which are incorporated hereto by reference.
